Innovative Eyewear Inc. (LUCY)vsNovartis AG ADR (NVS)
LUCY
Innovative Eyewear Inc.
$0.84
-2.03%
HEALTHCARE · Cap: $7.87M
NVS
Novartis AG ADR
$142.41
+3.14%
HEALTHCARE · Cap: $267.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1661477% more annual revenue ($56.69B vs $3.41M). NVS leads profitability with a 22.5% profit margin vs -225.3%. NVS earns a higher WallStSmart Score of 51/100 (C-).
LUCY
Avoid33
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+23.1%
Fair Value
$1.43
Current Price
$0.84
$0.59 discount
Margin of Safety
-53.2%
Fair Value
$93.54
Current Price
$142.41
$48.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 74.5% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -102.4% — below average capital efficiency
Negative free cash flow — burning cash
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : LUCY
The strongest argument for LUCY centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 74.5% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : LUCY
The primary concerns for LUCY are EPS Growth, Market Cap, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
LUCY profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.
LUCY carries more volatility with a beta of 2.74 — expect wider price swings.
LUCY is growing revenue faster at 74.5% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 33/100), backed by strong 22.5% margins. LUCY offers better value entry with a 23.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Innovative Eyewear Inc.
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Innovative Eyewear Inc. (LUCY) stands at the forefront of the smart eyewear sector, merging advanced technology with appealing aesthetics to meet the needs of modern, tech-savvy consumers. Its flagship product line, Lucyd, is designed to provide integrated audio features and seamless connectivity, offering a blend of convenience and style. Firmly focused on enhancing user experience and driving innovation, LUCY is well-positioned to leverage the growing demand for multifunctional eyewear, creating significant growth opportunities in a rapidly evolving market. As the trend towards smart, connected devices accelerates, LUCY’s strategic initiatives to promote its product offerings place it in a strong position for long-term competitiveness and success.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?